EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Cynata Therapeutics Limited (CYYNF) fair value: what the stock is really worth

As of Sep 25, 2026: fair value of Cynata Therapeutics Limited $0.00, price $0.00, upside -7.1%, quality 36 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US

CT Cynata Therapeutics Limited logo Thin data Sep 27, 2026

Cynata Therapeutics Limited

CYYNF · US

Low PriorityFair Value upside is limited and quality is weak.

·Fair value $0.0013 · Fairly valued (−7.1%)
!Quality 36/100
!Weak Growth (revenue 5y −23.1 %/yr)
!Low debt · negative free cash flow
!Trails peers (2/7)
!Narrow moat 3/100
!Evidence only low, so the estimate is less certain
!Weak on valuation: 24 out of 100
Watch Cynata Therapeutics Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$0.4650 $0.0014 Fair Value $0.0013 Jul 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

60‑month range $0.0014 – $0.4650 · the $0.0014 price screens above the $0.0013 fair value. Dashed = 300-day average. As of Sep 27, 2026.

Follow Cynata Therapeutics in your weekly email

Every Wednesday you see whether Cynata Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia.

Show more

Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host disease. It is also involved in the development of CYP-004, which is in Phase 3 clinical trial used for the treatment of osteoarthritis; CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds; and Diabetic Foot Ulcer which has completed phase 1 trial for the treatment of non-healing wounds on the feet/lower limbs. Further, it develops Cohort 1 which has completed Phase 1/2 for the treatment of kidney transplant. Cynata Therapeutics Limited has a license arrangement with Fujifilm corporation. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.

Stock analysis

Cynata Therapeutics Limited (CYYNF) currently trades at $0.0014, while our model-based Fair Value estimate is $0.0013, so the stock looks roughly fairly valued today (gap 7.7%).

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Quality & growth

The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Cynata Therapeutics Limited reported revenue of A$1.9M in FY2025 versus A$1.5M in FY2021, a compound +5.1%/yr. Reported net income was −A$9.4M in FY2025.

Key figures

Market cap $2.1M · P/S ratio 32.1 · EPS (TTM) $−0.0300 · Return on equity −113% · Return on assets (EBIT) −64.4% · Operating margin −150% · Revenue (TTM) A$1.7M · Revenue growth (YoY) −10.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).

What moves the price

The share trades about 99% below its 52-week high and at its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −7%, CYYNF screens richer than that median.

Notify me when CYYNF reaches fair value

Put CYYNF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 36/100

Of which business quality 40 · Market factors (momentum, volatility) 11

Profitability 12
Margins and returns on capital today
Quality Growth 29
Are margins and returns improving?
Cashflow 10
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 99
Disciplined investing over empire-building
Low Volatility 28
Calm price path (market factor)
Momentum 6
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−18.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−37.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−23.1%
Start year 2020 (pandemic). Over 10 years: +20.8% a year
Revenue growth 17 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−149.9% (2020) → −430.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch CYYNF, get fair value alerts →

Compare Cynata Therapeutics Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 576 stocks

Beats the industry median on 1/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 40 · Below median
Fair Value upside −7.1% · Above median
Profitability
Return on assets −62.1% · Bottom 25%
Operating margin (TTM) −150.2% · Bottom 25%
Growth and dividend
Revenue growth −10.0% · Below median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)24 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $527.67 $580.44 +10%
Regeneron Pharmaceuticals, Inc REGN $752.25 $1,275 +69%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$175.35 A$192.89 +10%
Samsung Biologics Co 207940 1,354,000 KRW 1,489,400 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cynata Therapeutics Limited · Fair Value
$0.0013 −7%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Cynata Therapeutics Limited Fair Value". https://www.fairvalue-calculator.com/stock/CYYNF

Frequently asked questions

Is Cynata Therapeutics Limited (CYYNF) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $0.0013 versus the last price from Sep 25, 2026 of $0.0014, about −7% upside (fairly valued).
What is the fair value of CYYNF?
Our model-based fair value for Cynata Therapeutics Limited is $0.0013 (as of Sep 27, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $0.0014.
What is the quality score of CYYNF?
Cynata Therapeutics Limited has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cynata Therapeutics Limited (CYYNF)?
Our model-based price target is the fair value of $0.0013 (as of Sep 27, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Cynata Therapeutics Limited stock forecast for 2026?
Our models put fair value at $0.0013, about −7% upside versus the last price from Sep 25, 2026 of $0.0014 (fairly valued). The calculation is refreshed regularly with new filings.
What is the revenue of Cynata Therapeutics Limited (CYYNF)?
Cynata Therapeutics Limited reported trailing-twelve-month revenue of about A$1.7M (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Cynata Therapeutics Limited (CYYNF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cynata Therapeutics Limited it is $0.0013 per share (as of Sep 27, 2026), against a price of $0.0014. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Cynata Therapeutics Limited stock overvalued or undervalued in 2026?
As of Sep 27, 2026, CYYNF trades above its calculated fair value: price $0.0014, fair value $0.0013, a gap of about −7% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CYYNF?
No. The price is what the market pays today ($0.0014); the fair value is what the company's own numbers justify ($0.0013). For Cynata Therapeutics Limited the two are $0.0001 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cynata Therapeutics Limited worth?
The market values Cynata Therapeutics Limited at about $2.1M (market capitalisation, as of Sep 27, 2026). Per share that is $0.0014; our models calculate a fair value of $0.0013 per share.
How solid is the balance sheet of Cynata Therapeutics Limited (CYYNF)?
Balance-sheet figures for Cynata Therapeutics Limited (as of Sep 27, 2026): return on equity −113.0%. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is CYYNF from its 52-week high?
Cynata Therapeutics Limited trades at $0.0014, about 99% below its 52-week high of $0.2225 and at the low of $0.0014 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0013 is for.
Which stocks are comparable to Cynata Therapeutics Limited?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cynata Therapeutics Limited stock attractive at the current price?
The data as of Sep 27, 2026: price $0.0014, calculated fair value $0.0013 (−7%), Quality Score 36/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CYYNF calculated?
We run Cynata Therapeutics Limited through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0013, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Cynata Therapeutics Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cynata Therapeutics Limited (CYYNF)?
The latest price we hold is from Sep 25, 2026 and stands at $0.0014. Our model-based fair value is $0.0013, about −7% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cynata Therapeutics Limited right now?
The price sits above even our optimistic bull case ($0.0013). The favourable scenario is already priced in. The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Cynata Therapeutics Limited

How large is the market capitalisation of Cynata Therapeutics Limited (CYYNF)?
The market capitalisation of Cynata Therapeutics Limited is $2.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cynata Therapeutics Limited (CYYNF)?
The price-to-sales ratio of Cynata Therapeutics Limited is 32.1 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Cynata Therapeutics Limited (CYYNF)?
Earnings per share at Cynata Therapeutics Limited are $−0.0300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Cynata Therapeutics Limited (CYYNF)?
The return on equity (ROE) of Cynata Therapeutics Limited is −113% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cynata Therapeutics Limited (CYYNF)?
On an EBIT basis the return on assets of Cynata Therapeutics Limited is −64.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cynata Therapeutics Limited (CYYNF)?
The operating margin of Cynata Therapeutics Limited is −150% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cynata Therapeutics Limited (CYYNF)?
Revenue at Cynata Therapeutics Limited is growing −10.0% versus a year earlier (3y avg −37.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Cynata Therapeutics Limited (CYYNF) generate?
The free cash flow of Cynata Therapeutics Limited is −A$8.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Cynata Therapeutics Limited (CYYNF) hold?
Cynata Therapeutics Limited holds more cash than debt, A$5.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Cynata Therapeutics Limited in the live analysis

One click puts Cynata Therapeutics Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.